BLOG

biospace

Setting the Stage for ASH 2022

On Monday, Elixirgen Therapeutics and its research collaborators will present data from the company’s lead candidate, EXG-34217, a first-in-human cell therapy that aims to extend telomere length in patients with telomere biology disorders.